Protecting Access to Affordable Medicines Act of 2020

Bill: 116-hr-8529
Sponsor: full_name: Rep. Butterfield, G. K. [D-NC-1]
Introduced: 2020-10-06
Policy area: Health
Subjects: Home and outpatient care

Inflation and prices

Medicaid

Prescription drugs

State and local government operations
Latest action: action_date: 2020-10-06
text: Referred to the House Committee on Energy and Commerce.

Summaries:
action_date: 2020-10-06
action_desc: Introduced in House
text: <p><b>Protecting Access to Affordable Medicines Act of 2020</b></p> <p>This bill prohibits additional rebates for certain drugs under the Medicaid Drug Rebate Program. Specifically, the bill prohibits additional rebates with respect to noninnovator multiple-source drugs (i.e., generics) for which the average manufacturer price is less than $1. </p>

tv_txt: I 116th CONGRESS 2d Session H. R. 8529 IN THE HOUSE OF REPRESENTATIVES October 6, 2020 Mr. Butterfield (for himself, Mr. Long , and Mr. Cárdenas ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend title XIX of the Social Security Act to prohibit additional rebates under the Medicaid program for certain noninnovator multiple source drugs.

1. Short title This Act may be cited as the Protecting Access to Affordable Medicines Act of 2020 . 2. Prohibition on additional rebate under Medicaid for certain noninnovator multiple source drugs Section 1927(c)(3)(C) of the Social Security Act ( 42 U.S.C. 1396r–8(c)(3)(C) ) is amended— (1) in clause (i), by striking The amount and inserting Subject to clause (v), the amount ; and (2) by adding at the end the following new clause: (v) Prohibition on additional rebate for certain noninnovator multiple source drugs With respect to a rebate period beginning on or after January 1, 2021, and a dosage form and strength of a covered outpatient drug described in clause (i), the amount of the rebate specified in subparagraph (A) for such dosage form and strength for such rebate period may not be increased if the average manufacturer price for a unit of such dosage form and strength for such rebate period is less than $1. .